Tempus Expands Leadership Team With the Appointment of Joel Dudley, PhD, as Senior Vice President of Research
22 août 2019 12h00 HE
|
Tempus
CHICAGO, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announces the...
Syapse Announces Research Collaboration with the FDA Focused on the Regulatory Use of Real-World Evidence
14 août 2019 06h00 HE
|
Syapse
SAN FRANCISCO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multi-year Research Collaboration Agreement...
Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer
12 août 2019 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology to Present at Wedbush PacGrow Healthcare Conference
07 août 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Seoul National University Hospital and Syapse Sign Multi-Year Renewal Agreement to Expand Access to Precision Medicine in South Korea
06 août 2019 08h00 HE
|
Syapse
Syapse and SNUH will work together to build Asia’s first learning health network of real-world data derived from the region’s leading precision oncology hospitals Co-hosted symposium of East Asian...
Notable Named To Fast Company’s Inaugural List Of The 50 Best Workplaces for Innovators
05 août 2019 10h45 HE
|
Notable Labs
SAN FRANCISCO, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment with a clinically validated platform that rapidly advances cancer drug development at a fraction of the...
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update
01 août 2019 16h30 HE
|
ARCA biopharma, Inc.
FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction (HFpEF)PRECISION-AF...
Kura Oncology Reports Second Quarter 2019 Financial Results and Provides Corporate Update
01 août 2019 16h05 HE
|
Kura Oncology, Inc.
- Registration-directed trial of tipifarnib in HRAS mutant HNSCC ongoing – – Positive Phase 2 trial of tipifarnib in AITL and CXCL12-driven PTCL support potential paths to registration – –...
Kura Oncology to Report Second Quarter 2019 Financial Results
25 juil. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia
24 juil. 2019 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...